Tebentafusp for uveal melanoma.

Published on Oct 8, 2021in Nature Reviews Clinical Oncology66.675
· DOI :10.1038/S41571-021-00572-3
David Killock9
Estimated H-index: 9
Sources
Abstract
📖 Papers frequently viewed together
20043.60Melanoma Research
1 Author (Bertil Damato)
2015Clinical Atlas of Canine and Feline Ophthalmic Disease
4 Authors (Douglas W. Esson, ..., Dacvo)
2010
4 Authors (Kavita Mishra, ..., Devron H. Char)
References1
Newest
BACKGROUND Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a low tumor mutational burden and a 1-year overall survival of approximately 50% in patients with metastatic uveal melanoma. Data showing a proven overall survival benefit with a systemic treatment are lacking. Tebentafusp is a bispecific protein consisting of an affinity-enhanced T-cell receptor fused to an anti-CD3 effector that can redirect T cells to target glycoprotein 100-positive cells. METHODS In this o...
Source
1
Cited By0
Newest
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.